Medicare AdvantageAdministrativeLow impact
MA07.044b, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·NJ · Pulmonology, Allergy & Immunology, Pediatrics +1 more·Medical Policy
We identified it
Jun 19, 2026
Summary
This is a routine annual reissue of Independence Blue Cross Medicare Advantage policy MA07.044b with no substantive changes to coverage criteria. The policy maintains coverage for exhaled nitric oxide (eNO/FeNO) testing for asthma diagnosis and management (up to 5 tests per 12 months), while exhaled breath condensate (EBC) and eNO for other respiratory conditions remain non-covered as experimental/investigational.
Action Required
No immediate action required. This is a routine annual policy reissuance with no coverage changes. Billing team should verify that current claim submission processes align with existing coverage criteria: CPT 95012 (exhaled nitric oxide) is covered for asthma diagnosis/management only up to 5 tests per 12-month period; CPT 83987 (exhaled breath condensate) remains non-covered. If not already implemented, ensure billing software denies claims for CPT 83987 and CPT 95012 when used for COPD, chronic cough, or when exceeding 5 tests annually.